Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, tolerability, pharmacokinetics and pharmacodynamics of omalizumab in mild to moderate asthma with high IgE/weight
2006-005588-24Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of omalizumab in allergic asthma and asthma, sponsored by Novartis. Primary endpoint: Safety and tolerability of omalizumab. Started Feb 2007; status: completed.
02
Drugs
omalizumab
03
Conditions
allergic asthmaasthma
Beyond the preview
Go deeper on 2006-005588-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005588-24.